

| | |
|---|----------|
| 1 Drugs in Common Use | 1 |
| 1.1 Antibiotics | 1 |
| Topical antibiotics; beta-lactamases; side-effects; renal elimination; hepatic disease and failure | |
| 1.2 Antihistamines | 9 |
| Use in the common cold and upper respiratory tract infections; special problems; interaction with other drugs; adverse effects on the nervous system; topical use; acute poisoning | |
| 1.3 Histamine ₂ -Receptor Blocking Agents | 13 |
| Cimetidine; ranitidine | |
| 1.4 Antacids | 16 |
| Aluminium toxicity; chronic aluminium toxicity; bismuth encephalopathy and neuropathy | |
| 1.5 Laxatives | 19 |
| Safety profiles; cathartic syndrome; chronic hypokalaemia; mineral oil deposits; phenolphthalein | |
| 1.6 Antidiarrhoeal Agents | 22 |
| Kaolin; pectin; bismuth, anticholinergics; opiates; diphenoxylate and atropine; iodochlorhydroxyquin; antidiarrhoeal/antibiotic combinations | |
| 1.7 Aspirin and the Acidic Non-steroidal Anti-inflammatory Agents | 25 |
| Gastrointestinal injury; sensitivity reactions; analgesic nephropathy; redistributional drug interactions; general considerations for use in chronic rheumatic conditions | |
| 1.8 Digitalis | 30 |
| Clinical signs of digitalis toxicity; early recognition of cardiotoxicity; contraindications to digitalis therapy; massive digitalis intoxication; digoxin and quinidine | |

| | | |
|------|---|----|
| 1.9 | Sympathomimetic Drugs | 33 |
| | Adrenaline; ephedrine; phenylpropanolamine; noradrenaline; isoprenaline; beta ₂ -selective agents; dopamine and dobutamine; clonidine | |
| 1.10 | Alpha-Adrenoreceptor Blocking Agents | 37 |
| | Phenoxybenzamine; prazosin; indoramin | |
| 1.11 | Beta-Adrenoreceptor Blocking Agents | 39 |
| 1.12 | Potassium Supplements | 40 |
| 1.13 | Nitrates | 41 |
| | Adverse Effects; Tolerance | |
| 1.14 | Calcium Antagonists | 42 |
| | Verapamil; nifedipine; perhexilene; prenylamine; diltiazem | |
| 1.15 | Benzodiazepines | 44 |
| | Guidelines for use; dependence | |
| 1.16 | Tricyclic Antidepressants | 46 |
| | Cardiotoxicity; postural hypotension; anticholinergic effects; epilepsy; acute withdrawal effects | |
| 1.17 | Methylphenidate | 49 |
| 1.18 | Anorectic Agents | 50 |
| | Sympathomimetic amines; safety; fenfluramine; phenylpropanolamine; comparative pharmacological effects | |
| 1.19 | Addition of Drugs to Intravenous Fluids | 55 |
| 1.20 | Parenteral Nutrition | 57 |
| | Micronutrient deficiencies; metabolic bone disease; hepatic dysfunction; fat overload syndrome | |
| 1.21 | Topical Corticosteroids | 61 |
| | Potency; activity; local toxicity; systemic toxicity; minimising risks of adverse effects; use in ophthalmology | |
| 1.22 | Methylene Blue | 65 |
| | Use in methaemoglobinaemia; toxicity | |
| 1.23 | Vitamins | 66 |
| | Vitamin A (retinol): requirements; hypervitaminosis A Vitamin B ₁₂ and folic acid Vitamin C: antiscorbutic activity; toxicity Vitamin D: Normal requirements; individual susceptibility; hypervitaminosis D Vitamin K: adverse effects; treatment of hypoprothrombinaemia | |

| | |
|--|-----------|
| 2 Drug Safety in Some Common Medical Conditions | 73 |
| 2.1 Heart Failure | 73 |
| Excessive diuresis; diuretic escape; hypokalaemia; digitalis toxicity; myocardial ischaemia; adverse drug-drug interactions; lack of response to therapy | |
| 2.2 Hypertension | 77 |
| Stepped approach to drug treatment; captopril; methyldopa; beta-adrenoreceptor blocking agents; frusemide; prazosin; minoxidil; drug treatment in the elderly | |
| 2.3 Cough | 84 |
| Codeine; mucolytic agents; antihistamines | |
| 2.4 Bronchial Asthma | 87 |
| Methylxanthines; combination anti-asthmatic preparations | |
| 2.5 Tuberculosis and Other Mycobacterial Infections ... | 91 |
| Drugs of choice; treatment failure; toxicity profiles; renal failure; hepatotoxicity; pregnancy | |
| 2.6 Fungal Infections | 96 |
| Amphotericin B; 5-fluorocytosine | |
| 2.7 Malaria | 98 |
| Cerebral malaria; adverse effects of antimalarial agents; prophylaxis in pregnancy | |
| 2.8 Urinary Tract Infections | 101 |
| Antimicrobial therapy of uncomplicated infections; repeated infections; catheter-associated infections; treatment in renal failure; nalidixic acid; nitrofurantoin | |
| 2.9 Cancer Chemotherapy | 106 |
| Resistance to cytotoxic agents; general guidelines | |
| 2.10 Iron-Deficiency Anaemia | 112 |
| Contraindications to iron; failed response; choice of an oral iron preparation; adverse effects of oral therapy; hazards of parenteral therapy; iron supplements | |
| 2.11 Diabetes Mellitus | 115 |
| Insulin allergy; insulin lipoatrophy and lipohypertrophy; insulin resistance; insulin hypoglycaemic reactions; the Somogyi effect; beta- adrenoreceptor blocking drugs and blood sugar control; sulphonylureas; lactic acidosis; chlorpropamide-alcohol flush | |
| 2.12 Gout | 125 |
| Colchicine; indomethacin; uricosuric agents; allopurinol | |

| | | |
|------|---|-----|
| 2.13 | Myasthenia Gravis | 129 |
| | Anticholinesterases; atropine; corticosteroids; other drugs affecting the myoneuronal junction | |
| 3 | Patients at Special Risk | 135 |
| 3.1 | Pregnant Women | 135 |
| | Drug injury to the fetus: drug usage in pregnancy Drug treatment of important medical conditions in pregnancy: severe vomiting and hyperemesis gravidarum; epilepsy; rheumatic conditions; tuberculosis; ulcerative colitis; anticoagulation; depression | |
| 3.2 | Breast-Feeding mothers | 141 |
| 3.3 | The Elderly | 144 |
| | Disinhibition reactions; neuropsychiatric syndromes; tranquilliser dependence; anticholinergic syndrome; hypoglycaemic syndromes; ocular effects; special issues in drug treatment; guidelines | |
| 3.4 | Motor Vehicle Drivers | 149 |
| 3.5 | Porphyrics | 150 |
| | Clinical guidelines; management of an acute attack; prediction | |
| 4 | Drug Injuries | 155 |
| 4.1 | Drug Fever | 155 |
| | Causes; pathogenesis; clinical features; predisposing factors; diagnosis; management; Herxheimer reaction; malignant hyperthermia; neuroleptic malignant syndrome | |
| 4.2 | Anaphylaxis and Anaphylactoid Reactions | 159 |
| | Pathogenesis; symptomatology; prediction and prevention; differential diagnosis; Hoigne's syndrome; serum sickness reactions; classification of allergic drug reactions | |
| 4.3 | Drug-Induced Diseases of the Skin | 168 |
| | Diagnosis and natural history; management of hypersensitivity | |
| 4.4 | Drug-Induced Vasculitis | 171 |
| | Clinical features; allopurinol hypersensitivity | |
| 4.5 | Drug-Induced Vomiting | 173 |
| | Metoclopramide; cannabinoids | |
| 4.6 | Central Anticholinergic Syndromes | 175 |
| | Toxic confusional state; disorders of temperature control; neuroleptic malignant syndrome; physostigmine | |

| | | |
|-----|--|-----|
| 4.7 | Drug-Induced Ototoxicity | 178 |
| | Diagnosis; aminoglycosides; salicylates; non-steroidal anti-inflammatory agents; antimalarials; loop diuretics | |
| 5 | Diagnosing Adverse Drug Reactions | 181 |
| | Classification; probability of association; severity; Berkson's bias | |
| | Subject Index | 187 |